Omnicell (NASDAQ:OMCL) Releases Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.150-0.250 for the period, compared to the consensus earnings per share estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Price Performance

Shares of OMCL stock opened at $35.01 on Friday. The company’s 50-day simple moving average is $39.01 and its two-hundred day simple moving average is $42.58. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company has a market capitalization of $1.64 billion, a P/E ratio of 129.67, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities analysts anticipate that Omnicell will post 1.09 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on OMCL shares. Benchmark reissued a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, March 24th. JPMorgan Chase & Co. lowered their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Bank of America cut their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.